Immix Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

Immix Biopharma

13/11/2024 15:53

* Immix Biopharma Inc  IMMX.OQ  reported a quarterly
adjusted loss
of 24 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -23 cents.  The lone analyst forecast for the quarter was
for a loss of 16 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Immix Biopharma Inc's reported EPS for the quarter was a
loss
of 24 cents​.
    * The company reported a quarterly loss of $7.15 million.
    * Immix Biopharma Inc shares had risen by 15.4% this
quarter and
lost 75.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 23.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Immix Biopharma
Inc is 7.00 
This summary was machine generated from LSEG data November 13 at
03:53 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.16          -0.24          Missed
 Jun. 30 2024      -0.21          -0.15          Beat
 Dec. 31 2023      -0.23          -0.23          Met